Literature DB >> 16761999

Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.

Albert J Czaja1, Herschel A Carpenter, S Breanndan Moore.   

Abstract

AIMS: To determine the clinical phenotype and outcome of patients with definite type 1 autoimmune hepatitis, who lack human leukocyte antigen (HLA) DR3 and DR4, and to assess the importance of HLA DR7 and DR13.
METHODS: Two hundred and seven adult patients were typed for DR3, DR4, DR7, and DR13 by DNA-based techniques. One hundred and two blood donors constituted a normal population.
RESULTS: Twenty-six patients lacked DR3 and DR4 (13%). Treatment failure occurred more commonly in these individuals than in the 68 patients with DR4 (20% vs. 3%, P = 0.03), and relapse after drug withdrawal was less frequent than in the 84 patients with DR3 (55% vs. 87%, P = 0.03). HLA DR13 occurred more often than in those with DR3 (54% vs. 15%, P = 0.0002) or DR4 (54% vs. 12%, P = 0.00005), and it was more frequent than in normal adults (54% vs. 22%, P = 0.003), including those without DR3 or DR4 (54% vs. 27%, P = 0.03). HLA DR7 was not associated with susceptibility or outcome.
CONCLUSIONS: White North American patients who lack DR3 and DR4 respond differently to corticosteroid treatment than patients with classical HLA phenotypes. HLA DR13 is common in these adult patients, and it may affect treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16761999     DOI: 10.1111/j.1478-3231.2006.01249.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

Review 1.  Influence of genes, sex, age and environment on the onset of autoimmune hepatitis.

Authors:  Kathie Béland; Pascal Lapierre; Fernando Alvarez
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

Review 2.  Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients.

Authors:  Albert J Czaja; Herschel A Carpenter; S Breanndan Moore
Journal:  Dig Dis Sci       Date:  2007-05-18       Impact factor: 3.199

4.  Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis.

Authors:  Yohei Furumoto; Toru Asano; Tomonori Sugita; Hiroshi Abe; Yoshimichi Chuganji; Kazuhiko Fujiki; Akihiko Sakata; Yoshio Aizawa
Journal:  BMC Gastroenterol       Date:  2015-10-21       Impact factor: 3.067

Review 5.  Type 2 autoimmune hepatitis: Genetic susceptibility.

Authors:  Pascal Lapierre; Fernando Alvarez
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

6.  Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial.

Authors:  Lydia T de Moraes Falcão; Debora R B Terrabuio; Marcio A Diniz; Andreia da Silva Evangelista; Fabricio G Souza; Eduardo L R Cancado
Journal:  JGH Open       Date:  2019-09-10

Review 7.  Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.

Authors:  Claudia Sirbe; Gelu Simu; Iulia Szabo; Alina Grama; Tudor Lucian Pop
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.